Fusion Pharmaceuticals Inc.
FUSN · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -5.16 | -0.11 | 0.08 | 0.20 |
| FCF Yield | -1.61% | -2.62% | -10.76% | -6.56% |
| EV / EBITDA | -51.17 | -24.75 | -10.59 | -13.79 |
| Quality | ||||
| ROIC | -11.59% | -10.83% | -7.89% | -10.31% |
| Gross Margin | 0.00% | 98.93% | 47.96% | -2,638.24% |
| Cash Conversion Ratio | 0.81 | 0.60 | 1.09 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | 160.21% | 191.60% | 37.68% | -10.94% |
| Free Cash Flow Growth | -55.87% | 4.86% | 4.84% | 23.87% |
| Safety | ||||
| Net Debt / EBITDA | -1.02 | 0.42 | -1.33 | -0.78 |
| Interest Coverage | -19.36 | -21.16 | -14.63 | -20.84 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.13 | 0.16 |
| Cash Conversion Cycle | -624.02 | -452.43 | 724.47 | 6,706.83 |